|
Demographics
|
|
Age, years, mean (SD)
|
61.3 (9.5)
|
61.0 (9.4)
|
61.4 (9.6)
|
0.36
|
|
Female, n (%)
|
618 (25.6)
|
239 (28.8)
|
379 (23.9)
|
0.008
|
|
Non-White Race, n (%)
|
299 (12.4)
|
140 (16.9)
|
159 (10.0)
|
< 0.0001
|
|
Medical history
|
|
Duration of diabetes, years, mean (SD)
|
8.5 (7.6)
|
12.6 (8.0)
|
6.4 (6.5)
|
< 0.0001
|
|
Prior MI, PCI, or CABG; n (%)
|
865 (35.8)
|
331 (39.9)
|
534 (33.6)
|
0.002
|
|
Heart failure; n (%)
|
348 (14.4)
|
141 (25.0)
|
207 (13.0)
|
0.01
|
|
Index ACS, n (%)
|
|
STEMI
|
932 (52.7)
|
313 (37.8)
|
619 (39.0)
|
0.24
|
|
Non-STEMI
|
836 (47.3)
|
304 (36.7)
|
532 (33.5)
|
0.24
|
|
Unstable angina
|
625 (26.0)
|
200 (24.1)
|
425 (26.7)
|
0.19
|
|
Revascularization for index ACS
|
1922 (79.5)
|
667 (80.5)
|
1255 (79.0)
|
0.42
|
|
Biometrics, mean (SD)
|
|
Body mass index, kg/m2
|
30.3 (4.9)
|
30.2 (4.9)
|
30.3 (4.9)
|
0.66
|
|
Systolic blood pressure, mmHg
|
129 (15)
|
130 (16)
|
129 (14)
|
0.24
|
|
Cardiovascular and diabetes medications, n (%)
|
|
High-intensity statin
|
2195 (90.2)
|
770 (92.9)
|
1425 (89.7)
|
0.01
|
|
ACE-inhibitor or ARB
|
2229 (92.2)
|
770 (92.9)
|
1459 (91.8)
|
0.40
|
|
Dual anti-platelet therapy
|
2122 (87.8)
|
735 (88.7)
|
1387 (87.3)
|
0.36
|
|
Metformin
|
1998 (82.6)
|
604 (72.9)
|
1394 (87.7)
|
< 0.0001
|
|
Sulfonylurea
|
707 (29.2)
|
177 (21.4)
|
530 (33.4)
|
< 0.0001
|
|
SGLT2 inhibitor
|
298 (12.3)
|
137 (16.5)
|
161 (10.1)
|
< 0.0001
|
|
GLP-1 receptor agonist
|
86 (3.6)
|
51 (6.2)
|
35 (2.2)
|
< 0.0001
|
|
Clinical chemistry, median (Q1–Q3)
|
|
Estimated GFR (mL/min/1.73m2)
|
98.3 (76.2–126.2)
|
95.7 (73.8–127.9)
|
99.7 (77.3–125.5)
|
0.23
|
|
Fasting glucose, mmol/L
|
7.5 (6.1–9.7)
|
8.7 (6.8–11.4)
|
7.0 (5.9–9.0)
|
< 0.0001
|
|
Hemoglobin A1c, %
|
7.3 (6.4–8.7)
|
8.4 (7.5–9.6)
|
6.9 (6.2–7.8)
|
< 0.0001
|
|
LDL cholesterol, mmol/L
|
1.7 (1.3–2.2)
|
1.7 (1.3–2.2)
|
1.7 (1.3–2.2)
|
0.62
|
